Tracey Sunderland

Alere San Diego, Inc. develops, manufactures, and markets, diagnostic products. The company was founded by Kim D. Blickenstaff and Gunars E. Valkirs on June 28, 1988 and is headquartered in San Diego, CA.

CardioKine, Inc. develops drugs and pharmaceuticals for the treatment and prevention of heart failure. The company was founded by Arthur Michael Feldman, James Mervis, Paul-Andre de Lame and Michael Juliano in 2004 and is headquartered in Pittsburgh, PA.

Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT.

Antipodean Pharmaceuticals, Inc. manufactures pharmaceutical products and provides pre clinical services. Its product MitoQ, which blocks mitochondrial oxidative damage and prevents cell death. The company was founded in 2002 and is headquartered in Menlo Park, CA.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Cerylid Biosciences Ltd. is an Australian pharmaceutical company that manufactures pharmaceutical products. The private company is based in Richmond, Australia.

GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge.

PolyBatics Ltd. engages in the design, development, manufacturing and marketing of bionanoparticles. Its products include Assign-bTB, PolyZyme-CALB, PolyBind-Z and PolyBind-G. The firm harnesses the natural power of cells to create natural polymer particles, or biobeads, covered with proteins engineered to perform specific functions. The comapny was founded by Tracy Thompson and Bernd H. A. Rehm on January 9, 2009 and is headquartered in Palmerston North, New Zealand.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Sanguine BioSciences, Inc. provides biomedical research services and develops drugs. The firm maintains a bio repository of frozen samples from donors in various disease indications such as PBMC, PBMC subtypes, plasma, serum, cerebral spinal fluid, blood units and DNA/RNA. The company was founded by Brian Neman and Gerald H. Lee in 2010 and is headquartered in Sherman Oaks, CA.

NovaMedica LLC operates as a pharmaceutical company. Its portfolio includes gastroenterology, ophthalmology, and neurology. The company was founded in 2012 and is headquartered in Moscow, Russian Federation.

Engender Technologies Ltd. engages in the research and development of gender selection especially in the dairy industry. The company was founded by Miriam Cather Simpson on October 6, 2011 and is headquartered in Auckland, New Zealand.

ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.

Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.

Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation.

Prevatex Pty Ltd. is an Australian company that focuses on restoring optimal gut health. The company is based in Geelong West, Australia. The company address the issue of the loss of important gut microbes due to changes in our modern lifestyle, such as bleaching of fresh foods, antibiotic use, and stress. The company was founded by James A. Campbell and Gregory Collier.